Prnewswire·2025-05-14 11:00Core Insights - ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation, and CellReady, has awarded three G-Rex Grants totaling $1,025,000 to faculty members at USC and CHLA to support cell and gene therapy initiatives [1][8] Grant Details - Dr. Mohamed Abou-el-Enein received a $300,000 G-Rex Grant to develop a non-viral manufacturing platform for CAR-T cell therapies, building on initial funding from the CIRM [2] - Dr. Saul Priceman was awarded a $275,000 G-Rex Grant to advance a CAR-T cell therapy for metastatic solid cancers into Phase 1/2 clinical trials, addressing manufacturing bottlenecks [4] - Dr. Shahab Asgharzadeh received a $250,000 G-Rex Grant for preclinical development of a CAR-T cell therapy targeting recurrent solid tumors in children and young adults [5] - Dr. Preet Chaudhary was granted $200,000 for the development and IND submission of a novel Synthetic Immune Receptor engineered T cell therapy for solid tumors [6] G-Rex Platform Significance - The G-Rex system is recognized for its efficiency, scalability, and cost-effectiveness in CAR-T manufacturing, enabling high-yield cell expansion and robust scale-up [3] - The G-Rex Grant Program has awarded nearly 200 grants and is extending with millions in additional funding, providing recipients access to a consortium of partners for support in CGT development [8][10] Industry Impact - The G-Rex manufacturing platform is utilized by over 800 organizations and is involved in approximately 50% of CGT clinical trials, contributing to the commercialization of CGT drugs [10] - ScaleReady aims to enhance CGT drug product development and manufacturing, saving time and costs for entities in the CGT field [10]